DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma

Wang,Hui; Dai,Yu-Yuan; Zhang,Wen-Qian; Hsu,Ping-Chih; Yang,Yi-Lin; Wang,Yu-Cheng; Chan,Geraldine; Au,Alfred; Xu,Zhi-Dong; Jiang,Shu-Juan; Wang,Wei; Jablons,David M.; You,Liang

doi:10.3892/ijo.2017.4021

DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma

Authors:
- Hui Wang
- Yu-Yuan Dai
- Wen-Qian Zhang
- Ping-Chih Hsu
- Yi-Lin Yang
- Yu-Cheng Wang
- Geraldine Chan
- Alfred Au
- Zhi-Dong Xu
- Shu-Juan Jiang
- Wei Wang
- David M. Jablons
- Liang You
View Affiliations

Affiliations: Department of Pulmonary Medicine, Affiliated Shandong Provincial Hospital, Shandong University, Shandong, P.R. China, Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA, Division of Diagnostic Pathology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA, Department of Respiratory Medicine, The Second Hospital of Shandong University, Shandong, P.R. China
Published online on: May 26, 2017 https://doi.org/10.3892/ijo.2017.4021
Pages: 91-103
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive cancer for which more effective treatments are needed. In this study, strong to moderate staining of MET and ERK5 was detected in 67.1 and 48% of the analyzed 73 human mesothelioma tumors, and significant correlation of MET and ERK5 expression was identified (P<0.05). We evaluated the doublecortin-like kinase 1 (DCLK1) expression in human mesothelioma tumors. Our results showed that 50.7% of the immunohistochemistry analyzed human mesothelioma tumors have strong to moderate staining of DCLK1, and its expression is significantly correlated with MET or ERK5 expression (P<0.05). Also, the upregulation of DCLK1 is correlated with poor prognosis in MPM patients (P=0.0235). To investigate whether DCLK1 is downstream of MET/ERK5 signaling in human mesothelioma, the effect of DCLK1 expression was analyzed after treatments with either the MET inhibitor XL184 or the ERK5 inhibitor XMD8-92 in human mesothelioma cell lines. Our results showed that the MET inhibitor XL184 reduced the expression of phospho‑ERK5 and DCLK1 expression in human mesothelioma cell lines. In addition, the ERK5 inhibitor XMD8-92 reduced the expression of phospho-ERK5 and DCLK1 expression in human mesothelioma cell lines. Furthermore, XML184 and XMD8-92 treatment impaired invasion and tumor sphere formation ability of H290 mesothelioma cells. These results suggest that DCLK1 is regulated by MET/ERK5 signaling in human mesothelioma, and the MET/ERK5/DCLK1 signaling cascade could be further developed into a promising therapeutic target against mesothelioma.

View Figures

View References

1	La Vecchia C and Boffetta P: Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma. Eur J Cancer Prev. 21:227–230. 2012. View Article : Google Scholar : PubMed/NCBI
2	Buikhuisen WA, Hiddinga BI, Baas P and van Meerbeeck JP: Second line therapy in malignant pleural mesothelioma: A systematic review. Lung Cancer. 89:223–231. 2015. View Article : Google Scholar : PubMed/NCBI
3	Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A and Hassan R: New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol. 182:1065–1077. 2013. View Article : Google Scholar : PubMed/NCBI
4	Campbell NP and Kindler HL: Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 32:102–110. 2011. View Article : Google Scholar : PubMed/NCBI
5	Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature. 411:355–365. 2001. View Article : Google Scholar : PubMed/NCBI
6	Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT and Salgia R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 13:41–59. 2002. View Article : Google Scholar
7	Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE and Jänne PA: Inhibition of the met receptor in mesothelioma. Clin Cancer Res. 11:8122–8130. 2005. View Article : Google Scholar : PubMed/NCBI
8	Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, Strizzi L, Penengo L, Tognon M, Mutti L, et al: SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA. 98:12032–12037. 2001. View Article : Google Scholar : PubMed/NCBI
9	Ramos-Nino ME, Blumen SR, Sabo-Attwood T, Pass H, Carbone M, Testa JR, Altomare DA and Mossman BT: HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol. 38:209–217. 2008. View Article : Google Scholar
10	Regan CP, Li W, Boucher DM, Spatz S, Su MS and Kuida K: Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci USA. 99:9248–9253. 2002. View Article : Google Scholar : PubMed/NCBI
11	Hayashi M, Kim SW, Imanaka-Yoshida K, Yoshida T, Abel ED, Eliceiri B, Yang Y, Ulevitch RJ and Lee JD: Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest. 113:1138–1148. 2004. View Article : Google Scholar : PubMed/NCBI
12	Roberts OL, Holmes K, Müller J, Cross DA and Cross MJ: ERK5 is required for VEGF-mediated survival and tubular morphogenesis of primary human microvascular endothelial cells. J Cell Sci. 123:3189–3200. 2010. View Article : Google Scholar : PubMed/NCBI
13	Rovida E, Spinelli E, Sdelci S, Barbetti V, Morandi A, Giuntoli S and Dello Sbarba P: ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. J Immunol. 180:4166–4172. 2008. View Article : Google Scholar : PubMed/NCBI
14	Sureban SM, May R, Lightfoot SA, Hoskins AB, Lerner M, Brackett DJ, Postier RG, Ramanujam R, Mohammed A, Rao CV, et al: DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 71:2328–2338. 2011. View Article : Google Scholar : PubMed/NCBI
15	Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, et al: DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology. 146:245–256. 2014. View Article : Google Scholar
16	May R, Riehl TE, Hunt C, Sureban SM, Anant S and Houchen CW: Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells. 26:630–637. 2008. View Article : Google Scholar
17	Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG, et al: DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PLoS One. 8:e739402013. View Article : Google Scholar : PubMed/NCBI
18	Nakanishi Y, Seno H, Fukuoka A, Ueo T, Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, et al: Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet. 45:98–103. 2013. View Article : Google Scholar
19	Vega KJ, May R, Sureban SM, Lightfoot SA, Qu D, Reed A, Weygant N, Ramanujam R, Souza R, Madhoun M, et al: Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma. J Gastroenterol Hepatol. 27:773–780. 2012. View Article : Google Scholar :
20	Sureban SM, May R, Ramalingam S, Subramaniam D, Natarajan G, Anant S and Houchen CW: Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology. 137:649–659. 659.e641–642. 2009. View Article : Google Scholar : PubMed/NCBI
21	Sureban SM, May R, Mondalek FG, Qu D, Ponnurangam S, Pantazis P, Anant S, Ramanujam RP and Houchen CW: Nano-particle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnology. 9:402011. View Article : Google Scholar
22	Ali N, Allam H, May R, Sureban SM, Bronze MS, Bader T, Umar S, Anant S and Houchen CW: Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J Virol. 85:12292–12303. 2011. View Article : Google Scholar : PubMed/NCBI
23	Li T, Li H, Wang Y, Harvard C, Tan JL, Au A, Xu Z, Jablons DM and You L: The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. J Pathol. 223:519–530. 2011. View Article : Google Scholar : PubMed/NCBI
24	Varesano S, Salvi S, Boccardo S, Ravetti JL, Ferro P, Canessa PA, Fedeli F, Pistillo MP and Roncella S: Amplification of MET in a Patient with Malignant Pleural Mesothelioma. J Thorac Oncol. 10:e103–e104. 2015. View Article : Google Scholar : PubMed/NCBI
25	Kawakami H, Okamoto I, Okamoto W, Tanizaki J, Nakagawa K and Nishio K: Targeting MET amplification as a new oncogenic driver. Cancers (Basel). 6:1540–1552. 2014. View Article : Google Scholar
26	Matsumoto K and Nakamura T: NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 94:321–327. 2003. View Article : Google Scholar : PubMed/NCBI
27	Carbone M and Yang H: Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 18:598–604. 2012. View Article : Google Scholar
28	Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ and Fisher DE: Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 70:639–645. 2010. View Article : Google Scholar : PubMed/NCBI
29	Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, et al: Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 30:1097–1105. 2009. View Article : Google Scholar : PubMed/NCBI
30	Liu X, Newton RC and Scherle PA: Developing c-MET pathway inhibitors for cancer therapy: Progress and challenges. Trends Mol Med. 16:37–45. 2010. View Article : Google Scholar
31	Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, et al: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 10:2298–2308. 2011. View Article : Google Scholar : PubMed/NCBI
32	Trump DL: Commentary on 'Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial'. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL and Hussain M: University of Michigan; Ann Arbor, MI: J Clin Oncol. 2013.31(4): 412–9. View Article : Google Scholar : Epub 2012 Nov 19. Urol Oncol. 31:18482013. View Article : Google Scholar
33	Dai J, Zhang H, Karatsinides A, Keller JM, Kozloff KM, Aftab DT, Schimmoller F and Keller ET: Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res. 20:617–630. 2014. View Article : Google Scholar :
34	Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, et al: Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J Clin Oncol. 31:412–419. 2013. View Article : Google Scholar
35	Vaishampayan U: Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep. 15:76–82. 2013. View Article : Google Scholar : PubMed/NCBI
36	Mughal A, Aslam HM, Sheikh A, Khan AM and Saleem S: c-Met inhibitors. Infect Agent Cancer. 8:132013. View Article : Google Scholar : PubMed/NCBI
37	U.S. Food and Drug Administration (FDA): Cabozantinib. CABOMETYX. 2016, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm.
38	Whyte J, Bergin O, Bianchi A, Mcnally S and Martin F: Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res. 11:2092009. View Article : Google Scholar : PubMed/NCBI
39	Javaid S, Zhang J, Smolen GA, Yu M, Wittner BS, Singh A, Arora KS, Madden MW, Desai R, Zubrowski MJ, et al: MAPK7 regulates EMT features and modulates the generation of CTCs. Mol Cancer Res. 13:934–943. 2015. View Article : Google Scholar : PubMed/NCBI
40	Kato Y, Tapping Ri, Huang S, Watson MH, Ulevitch RJ and Lee JD: Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature. 395:713–716. 1998. View Article : Google Scholar : PubMed/NCBI
41	Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ and Lee JD: BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 16:7054–7066. 1997. View Article : Google Scholar
42	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI
43	Deng X, Yang Q, Kwiatkowski N, Sim T, McDermott U, Settleman JE, Lee JD and Gray NS: Discovery of a benzo[e] pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of Big MAP kinase 1. ACS Med Chem Lett. 2:195–200. 2011. View Article : Google Scholar : PubMed/NCBI
44	Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, Yates JR III, Gray NS and Lee JD: Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 18:258–267. 2010. View Article : Google Scholar : PubMed/NCBI
45	Weygant N, Qu D, Berry WL, May R, Chandrakesan P, Owen DB, Sureban SM, Ali N, Janknecht R and Houchen CW: Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer. 13:1032014. View Article : Google Scholar : PubMed/NCBI
46	Thu KL, Radulovich N, Becker-Santos DD, Pikor LA, Pusic A, Lockwood WW, Lam WL and Tsao MS: SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/β-catenin signaling. Oncogene. 33:279–288. 2014. View Article : Google Scholar
47	Qu D, Johnson J, Chandrakesan P, Weygant N, May R, Aiello N, Rhim A, Zhao L, Zheng W, Lightfoot S, et al: Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocar-cinoma and widely expressed on circulating tumor cells. PLoS One. 10:e01189332015. View Article : Google Scholar
48	Shukla A, Miller JM, Cason C, Sayan M, MacPherson MB, Beuschel SL, Hillegass J, Vacek PM, Pass HI and Mossman BT: Extracellular signal-regulated kinase 5: A potential therapeutic target for malignant mesotheliomas. Clin Cancer Res. 19:2071–2083. 2013. View Article : Google Scholar : PubMed/NCBI
49	Boguslawski G, Mcglynn PW, Harvey KA and Kovala AT: SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro. J Biol Chem. 279:5716–5724. 2004. View Article : Google Scholar
50	McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263–1284. 2007. View Article : Google Scholar
51	Yang Q and Lee JD: Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin Cancer Res. 17:3527–3532. 2011. View Article : Google Scholar : PubMed/NCBI
52	Sureban SM, May R, Weygant N, Qu D, Chandrakesan P, Bannerman-Menson E, Ali N, Pantazis P, Westphalen CB, Wang TC, et al: XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Lett. 351:151–161. 2014. View Article : Google Scholar : PubMed/NCBI